Domov › Nemalobunkový karcinóm pľúc › New Hampshire
Klinické štúdie Nemalobunkový karcinóm pľúc v štáte New Hampshire
17 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v štáte New Hampshire.
Mestá v štáte New Hampshire
Oficiálny text štúdie (anglicky)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center /ID# 277673, Lebanon
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 10. 2026 · NCT07155187Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 10. 2026 · NCT04267848Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Dartmouth-Hitchcock Medical Center, Lebanon
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT06881784A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Dartmouth Hitchcock Medical Center, Lebanon
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06667076Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06890598Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Lebanon
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT06767514A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- Dartmouth Hitchcock Medical Center, Lebanon
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT04302025A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Dartmouth Hitchcock Medical, Lebanon
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06253871A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06119581KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04165798KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04165070Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 6. 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 5. 2026 · NCT06116682Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
Prebieha náborFáza 2
18 Minutes · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT06031688A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Dartmouth Hitchcock, Lebanon
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 4. 2026 · NCT06362369A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- Dartmouth Hitchcock Medical Center, Lebanon
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 3. 2026 · NCT05948865Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.